The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Increased risk of leukemia among sickle cell disease patients in California
Abstract
To the editor: Due to improvements in treatment and care, the life expectancy of patients with sickle cell disease (SCD) has improved over the last 50 years[1][1] such that many patients now survive to an age where they are at an increased risk for cancer.[2][2] Previously reported small case
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous work has suggested that individuals with SCD may be at increased risk of developing myeloid malignancies41,42.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [41]
Citations
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Research works printed but not linked: 22
- Paulukonis, 2016, Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008, Public Health Rep, 131, 367, 10.1177/003335491613100221 · DOI
- Chen, 2005, Chronic myelogenous leukemia in sickle cell anemia, Arch Pathol Lab Med, 129, 423, 10.5858/2005-129-423-CMLISC · DOI
- Moschovi, 2001, Hodgkin’s disease in a child with sickle cell disease treated with hydroxyurea [published correction appears in Pediatr Hematol Oncol. 2007;24(8):651], Pediatr Hematol Oncol, 18, 371, 10.1080/088800101316921985 · DOI
- Stricker, 1986, Hematologic malignancy in sickle cell disease: report of four cases and review of the literature, Am J Hematol, 21, 223, 10.1002/ajh.2830210212 · DOI
- Wilson, 2000, Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea, Ann Intern Med, 133, 925, 10.7326/0003-4819-133-11-200012050-00029 · DOI
- Schultz, 2003, Malignancy in patients with sickle cell disease, Am J Hematol, 74, 249, 10.1002/ajh.10427 · DOI
- Seminog, 2016, Risk of individual malignant neoplasms in patients with sickle cell disease: English National Record Linkage Study, J R Soc Med, 109, 303, 10.1177/0141076816651037 · DOI · Paper page
- Brunson, 2017, Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality, Br J Haematol, 178, 319, 10.1111/bjh.14655 · DOI
- Adesina, 2017, Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California, Blood Adv, 1, 1287, 10.1182/bloodadvances.2017005256 · DOI
- Paulukonis, 2014, Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH), Pediatr Blood Cancer, 61, 2271, 10.1002/pbc.25208 · DOI
- Eisenbrown, 2015, The accuracy of using ICD-9-CM codes to determine genotype and fever status of patients with sickle cell disease, Pediatr Blood Cancer, 62, 924, 10.1002/pbc.25432 · DOI
- California Cancer Registry, 2015, California Cancer Reporting System Standards: Abstracting and Coding Procedures for Hospitals
- Breslow, 1987, Statistical methods in cancer research. Volume II--The design and analysis of cohort studies, IARC Sci Publ, 1
- Brandow, 2010, Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities, Expert Rev Hematol, 3, 255, 10.1586/ehm.10.22 · DOI
- Lanzkron, 2008, Systematic review: hydroxyurea for the treatment of adults with sickle cell disease, Ann Intern Med, 148, 939, 10.7326/0003-4819-148-12-200806170-00221 · DOI
- Platt, 2000, Sickle cell anemia as an inflammatory disease, J Clin Invest, 106, 337, 10.1172/JCI10726 · DOI
- Kundu, 2012, Emerging avenues linking inflammation and cancer, Free Radic Biol Med, 52, 2013, 10.1016/j.freeradbiomed.2012.02.035 · DOI
- Crusz, 2015, Inflammation and cancer: advances and new agents, Nat Rev Clin Oncol, 12, 584, 10.1038/nrclinonc.2015.105 · DOI · Paper page
- Aggarwal, 2006, Inflammation and cancer: how hot is the link?, Biochem Pharmacol, 72, 1605, 10.1016/j.bcp.2006.06.029 · DOI · Paper page
- Chung, 2015, Thalassaemia and risk of cancer: a population-based cohort study, J Epidemiol Community Health, 69, 1066, 10.1136/jech-2014-205075 · DOI
- Zacharski, 2008, Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial, J Natl Cancer Inst, 100, 996, 10.1093/jnci/djn209 · DOI · Paper page
- Terman, 2013, Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response, PLoS One, 8, e52543, 10.1371/journal.pone.0052543 · DOI
Cited by
Hsieh, M. M., Bonner, M., Pierciey, F. J., Uchida, N., Rottman, J., Demopoulos, L., Schmidt, M., Kanter, J., Walters, M. C., Thompson, A. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001330 · Cited by 152
Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy
Gupta, A. O., Raymond, G., Pierpont, E. I., Kemp, S., McIvor, R. S., Rayannavar, A., Miller, B., Lund, T. C., & Orchard, P. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2124857 · Cited by 67
“disease might be at a higher risk of developing leukemia than the general population at baseline [87].”
BackgroundClonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
Spencer Chapman, M., Cull, A. H., Ciuculescu, M. F., Esrick, E. B., Mitchell, E., Jung, H., O’Neill, L., Roberts, K., Fabre, M. A., Williams, N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02636-6 · Cited by 67
Metadata
- Authors
- Brunson, A., Keegan, T. H. M., Bang, H., Mahajan, A., Paulukonis, S., & Wun, T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-09-28
- Volume
- 130
- Issue
- 13
- Pages
- 1597-1599
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 139
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review